We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tessa Therapeutics

News List

Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer prnasia
December 18, 2020
Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, today announced the appointment of David McIntyre as its Chief Financial Officer.
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma prnasia
February 29, 2020
Tessa expects to initiate its pivotal Phase II multi-site trial in the fourth quarter of 2020.
Tessa Therapeutics, Baylor College of Medicine present results for the treatment of HER2-positive solid tumors biospectrumasia
May 06, 2019
The results of the preclinical study, a collaboration between Tessa Therapeutics and Baylor College of Medicine, were presented at the 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Washington, D.C.
Tessa Therapeutics collaborates with MSD to treat Cervical Cancer biospectrumasia
April 16, 2019
The collaboration will evaluate the safety and efficacy of Tessa's armored human papillomavirus-specific T cell (HPVST) therapy combined with MSD's……